Navamedic ASA

Equities

NAVA

NO0010205966

Pharmaceuticals

Market Closed - Oslo Bors 10:45:00 2024-04-23 am EDT 5-day change 1st Jan Change
34.2 NOK +0.29% Intraday chart for Navamedic ASA +1.79% -6.81%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Ingerø Reiten Investment Divests Navamedic Stake in NOK95 Million Deal MT
An unknown buyer acquired unknown minority stake in Navamedic ASA (OB:NAVA) from Ingerø Reiten Investment Company As for NOK 95 million. CI
Navamedic ASA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Navamedic Acquires Rights to Distribute Erectile Dysfunction Treatment in Nordic Countries MT
Navamedic ASA Acquires Rights to Market and Distribute Eroxon in the Nordic Countries CI
Navamedic ASA Renews Contract Signed with Vitaflo International Limited CI
Navamedic Enters Agreement with Orion for Distribution of Parkinson's Drug Across Europe MT
Navamedic ASA and Orion Corporation Sign Non-Binding Term Sheet for Flexilev® in Europe CI
Navamedic ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Navamedic ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Navamedic ASA Elects Åsa Kornfeld as Members of its Board of Directors CI
Navamedic Secures Ownership of Sweden’s Sensidose MT
Navamedic ASA (OB:NAVA) completed the acquisition of Sensidose AB. CI
EQL Pharma Closes Sensidose Bid, to Accept Navamedic Offer MT
Navamedic ASA Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Norway's Navamedic Lifts Offer for Remaining Sensidose Shares MT
Sweden’s EQL Pharma Increases Bid for Sensidose MT
Navamedic Raises Takeover Offer for Sensidose, Agrees to Buy 57% Stake MT
Navamedic Offers to Buy Sensidose for SEK75 Million MT
Navamedic ASA (OB:NAVA) made an offer to acquire Sensidose AB for SEK 96 million. CI
Navamedic ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Navamedic ASA Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Navamedic ASA Launches Modifast in Norway CI
Navamedic ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Navamedic ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Chart Navamedic ASA
More charts
Navamedic ASA is a Norway-based pharmaceutical company. It is a supplier of products delivered to hospitals and pharmacies. Navamedic’s product portfolio consists of prescription and Over The Counter (OTC) pharmaceuticals as well as other healthcare products registered as medical nutrition, medical devices, food supplements or cosmetics. The Company’s offering is divided into four product areas: Consumer Health, Specialty Pharma, Medical Nutrition and Branded Generics. The Company has one business segment which is the Pharma division. Navamedic ASA is present in all Nordic countries, the Baltics and Benelux. The Company has two subsidiaries, Navamedic AB, through which the Company distributes more than 40 products and a Norway-based Novicus Pharma AS.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
34.2 NOK
Average target price
49 NOK
Spread / Average Target
+43.27%
Consensus
  1. Stock Market
  2. Equities
  3. NAVA Stock
  4. News Navamedic ASA
  5. Navamedic Signs Market Making Agreement with Norne Securities